April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Jennifer Buell: BOTENSILIMAB is changing treatment landscape in MSS colon cancer
Apr 4, 2025, 09:40

Jennifer Buell: BOTENSILIMAB is changing treatment landscape in MSS colon cancer

Jennifer Buell, President and Chief Executive Officer of MiNK Therapeutics and Executive Council at Agenus, shared a post on X:

MSS colon cancer has long resisted immunotherapy.;

BOTENSILIMAB is changing this:

  • 29% pCR in (UNICORN).
  • 100% RFS at 18.2 mos (NEST).
  • 19% ORR in r/r mCRC.
  • 71% ORR w/ chemo + targeted Tx in 1L CRC.”

More updates on Botensilimab.